We found that the characteristic gene expression signature that distinguished short- and long-lived DNMT3A-mutated TCGA AML patients also enabled to separate the 63 DNMT3A-mutant AML patients from the University Hospital of Ulm into a short- and long-lived subgroup that differed significantly in survival (Fig. 5B, log-rank test: P < 0.03). The gene discussed is DNMT3A; the disease is acute myeloid leukemia.